A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

被引：0
|
作者：
Nadeem, Omar
Mo, Clifton C.
Laubach, Jacob P.
Bianchi, Giada
Redd, Robert
Barth, Peter
Bayliss, Trevor J.
Sanchorawala, Vaishali
Shune, Leyla
Distaso, Alexandra
Dalton, Virginia
Sperling, Adam S.
Amweg, Laura
McKenney, Mary
Colson, Kathleen
Millard, Ella L.
Hou, Isabella
Savell, Alexandra
Masone, Kelly
Munshi, Nikhil C.
Ghobrial, Irene M.
Anderson, Kenneth
Richardson, Paul G.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141549
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Yee, Andrew
    Laubach, Jacob
    Nooka, Ajay
    O'Donnell, Elizabeth
    Harrington, Cynthia
    Agyemang, Emerentia
    Burke, Jill
    Gammon, Marilyn
    Lively, Kathleen
    Packer, Lisette
    Bishop, James
    Bernstein, Zachary
    Lyons, Rebecca
    Wright, Alexandra
    McVey, Cailin
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S58 - S59
  • [23] A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)
    Voorhees, Peter M.
    Suman, Vera J.
    Tuchman, Sascha A.
    Laubach, Jacob P.
    Hassoun, Hani
    Efebera, Yvonne A.
    Mulkey, Flora
    Bova-Solem, Misty
    Santo, Katelyn
    Carlisle, Destin
    McCarthy, Philip L.
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : 1595 - 1603
  • [24] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
    Dimopoulos, Meletios
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ardizzoia, Antonio
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Li, Yan
    Bacon, Pamela
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
  • [25] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
  • [26] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
    Derman, Benjamin A.
    Chari, Ajai
    Zonder, Jeffrey
    Major, Ajay
    Stefka, Andrew T.
    Jiang, Ken
    Karrison, Theodore
    Jasielec, Jagoda
    Jakubowiak, Andrzej
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
  • [27] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [28] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Ball, Edward D.
    Larson, Sarah M.
    Sirianni, Lindsey
    Mulroney, Carolyn M.
    Costello, Caitlin L.
    BLOOD, 2023, 142
  • [29] Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
    Baz, Rachid
    Martin, Thomas G.
    Alsina, Melissa
    Shain, Kenneth H.
    Cho, Hearn J.
    Wolf, Jeffrey L.
    Mahindra, Anuj
    Chari, Ajai
    Sullivan, Daniel M.
    Nardelli, Lisa A.
    Lau, Kenneth
    Zhao, Xiuhua
    Lin, Hui-Yi
    Jagannath, Sundar
    BLOOD, 2014, 124 (21)
  • [30] A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Cho, Hearn Jay
    Parekh, Samir
    Lau, Kenneth
    Morgan, Gillian
    Catamero, Donna
    Cortes, Melissa
    Curtis, Meredith
    Escalon, Juliet
    Florendo, Erika
    Verina, Daniel
    Stevens, Nadege
    Chan, Elaine
    Garcia, Katarzyna
    La, Lisa
    Shields, Marisa
    Strumolo, Gina
    Jagannath, Sundar
    BLOOD, 2016, 128 (22)
12345